The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof: ##STR00001## wherein G is selected from the group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, and a 8- to 11-membered heteroaryl bicyclic group; wherein G may be substituted by (R.sub.2).sub.p, which can be the same or different; R.sub.1 is hydrogen or C.sub.1-4 alkyl; R.sub.2 is halogen, hydroxy, cyano, C.sub.1-4alkyl, haloC.sub.1-4alkyl, C.sub.1-4alkoxy, haloC.sub.1-4alkoxy, C.sub.1-4alkanoyl or SF.sub.5; or corresponds to R.sub.8; R.sub.5 is hydrogen or C.sub.1-4 alkyl; R.sub.6 is hydrogen or C.sub.1-4 alkyl; R.sub.7 is selected from the group consisting of: hydrogen, fluorine, and C.sub.1-4 alkyl; or corresponds to X, X.sub.1, X.sub.2 or X.sub.3; wherein X corresponds to: ##STR00002## X.sub.1 corresponds to: ##STR00003## X.sub.2 corresponds to: ##STR00004## X.sub.3 corresponds to: ##STR00005## R.sub.3 is hydrogen or C.sub.1-4 alkyl; or corresponds to X or X.sub.1; R.sub.4 is hydrogen or C.sub.1-4 alkyl; or corresponds to X or X.sub.1; R.sub.8 is a 5-6 membered heterocycle group, which may be substituted by one or two substituents selected from the group consisting of: halogen, cyano, C.sub.1-4alkyl, haloC.sub.1-4alkyl, C.sub.1-4alkoxy and C.sub.1-4alkanoyl; R.sub.9 is C.sub.1-4alkyl; R.sub.10 is hydrogen, C.sub.1-4alkyl, C.sub.3-6cycloalkyl or C.sub.3-6cycloalkylC.sub.1-3alkyl; R.sub.11 is haloC.sub.1-2alkyl; p is an integer from 0 to 5; and n is 1 or 2;and processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors.